Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.66 |
| ▸ | MEN1 | O00255 | 6/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5461095 | 0.96 | KMT2A (0.61) | KMT2AMEN1ATMAKR1C3POLB | |
| SCHEMBL5467408 | 0.95 | ALDH1A1 (0.62) | KMT2AMEN1ATMAKR1C3POLB | |
| SCHEMBL5474904 | 0.93 | KMT2A (0.66) | KMT2AMEN1ATMAKR1C3POLB | |
| SCHEMBL5461708 | 0.85 | ALDH1A1 (0.57) | KMT2AMEN1ATMAKR1C3POLB | |
| SCHEMBL5472415 | 0.83 | LMNA (0.54) | KMT2AMEN1ATMAKR1C3POLB | |
| SCHEMBL5467636 | 0.83 | LMNA (0.56) | KMT2AMEN1ATMAKR1C3POLB | |
| SCHEMBL5478426 | 0.83 | KMT2A (0.57) | KMT2AMEN1ATMAKR1C3POLB | |
| SCHEMBL5469312 | 0.83 | LMNA (0.56) | KMT2AMEN1ATMAKR1C3POLB | |
| SCHEMBL5476139 | 0.83 | LMNA (0.56) | KMT2AMEN1ATMPOLBLMNA | |
| SCHEMBL5472744 | 0.82 | KMT2A (0.57) | KMT2AMEN1ATMAKR1C3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062258-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090062258-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1847541-A1 | FUSED PYRIMIDINE DERIVATIVE AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | KMT2A 1132/4885MEN1 1223/4885ATM 2678/4885 |
| US-20090062258-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | GNRHR, FSHR, NPY4R | KMT2A 3073/4885MEN1 1766/4885ATM 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.